As you said @stocksa the extensive trial timeline blowout could be due to a combination of factors.
But I’m merely pointing out that Silvio, the CEO of MSB announced to the ASX back in April the anticipation of enrolment completion of the COVID ARDS trial would be July-Aug 2020. Now, somehow, it’s Jan-Mar 2021 with no apparent explanation that I recall.
Take it up with Silvio. Not me.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-667
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.055(3.77%) |
Mkt cap ! $1.729B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.54 | $1.45 | $6.072M | 4.049M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5951 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 133644 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |